Literature DB >> 18343941

Analysis of the prognostic factors and evaluation of surgical treatment for synchronous liver metastases from gastric cancer.

Kentaro Ueda1, Makoto Iwahashi, Mikihito Nakamori, Masaki Nakamura, Teiji Naka, Koichiro Ishida, Toshiyasu Ojima, Hiroki Yamaue.   

Abstract

BACKGROUND AND AIMS: Whether or not a synchronous resection of liver metastases from gastric cancer provides a survival benefit has been a key issue. We identify the significant prognostic factors and clarify the beneficial effect on the survival of liver surgical treatment.
MATERIALS AND METHODS: We reviewed 72 patients who underwent a gastrectomy for gastric cancer with synchronous liver metastases and classified the liver metastases into three grades, such as H1: metastases were limited to one of the lobes, H2: there were a few scattered metastases in both lobes, and H3: there were numerous scattered metastases.
RESULTS: H1, 2 metastases, and an absence of peritoneal dissemination (P0) were significantly independent prognostic factors for liver metastases of gastric cancer. In addition, the cumulative 1 and 5-year survival rates of liver surgical treatment (hepatic resection and/or microwave coagulation therapy) were 80.0% and 60.0%, whereas the survival rates for non-hepatic surgical treatment were 36.4% and 0% in 26 patients with H1, 2, and P0. In those patients, the radical operation, the solitary metastatic liver tumor, and no-distant lymph node metastases were independent prognostic determinants of survival.
CONCLUSION: The radical operation including the surgical treatment for metastatic liver tumors should be performed to improve the prognosis in gastric cancer patients with synchronous H1, 2, and P0.

Entities:  

Mesh:

Year:  2008        PMID: 18343941     DOI: 10.1007/s00423-008-0311-9

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  23 in total

1.  Management of gastric cancer patients with synchronous hepatic metastasis: a retrospective study.

Authors:  M Rafique; W Adachi; S Kajikawa; M Kobayashi; S Koike; T Kuroda
Journal:  Hepatogastroenterology       Date:  1995 Sep-Oct

2.  Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients.

Authors:  L E Harrison; M F Brennan; E Newman; J G Fortner; A Picardo; L H Blumgart; Y Fong
Journal:  Surgery       Date:  1997-06       Impact factor: 3.982

3.  Prognostic studies on gastric cancer with concomitant liver metastases.

Authors:  S Fujisaki; R Tomita; T Nezu; K Kimizuka; E Park; M Fukuzawa
Journal:  Hepatogastroenterology       Date:  2001 May-Jun

4.  Benefits and limits of hepatic resection for gastric metastases.

Authors:  S Ambiru; M Miyazaki; H Ito; K Nakagawa; H Shimizu; H Yoshidome; Y Shimizu; N Nakajima
Journal:  Am J Surg       Date:  2001-03       Impact factor: 2.565

5.  Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma.

Authors:  T Shibata; T Niinobu; N Ogata; M Takami
Journal:  Cancer       Date:  2000-07-15       Impact factor: 6.860

6.  Percutaneous microwave coagulation therapy for solitary metastatic liver tumors from colorectal cancer: a pilot clinical study.

Authors:  T Seki; M Wakabayashi; T Nakagawa; M Imamura; T Tamai; A Nishimura; N Yamashiki; K Inoue
Journal:  Am J Gastroenterol       Date:  1999-02       Impact factor: 10.864

7.  Synchronous, metachronous, and multiple hepatic resections of liver tumors originating from primary gastric tumors.

Authors:  S D Bines; G England; D J Deziel; T R Witt; A Doolas; D L Roseman
Journal:  Surgery       Date:  1993-10       Impact factor: 3.982

8.  Evaluation of treatment for synchronous hepatic metastases from gastric cancer with special reference to long-term survivors.

Authors:  Katsuyuki Kunieda; Shigetoyo Saji; Yasuyuki Sugiyama; Shinji Osada; Jun Sano; Narutoshi Nagao; Takao Takahashi; Yukihiro Takagi; Yasuaki Arai
Journal:  Surg Today       Date:  2002       Impact factor: 2.549

9.  Hepatic resection for metastatic tumours from gastric cancer: analysis of prognostic factors.

Authors:  T Ochiai; M Sasako; S Mizuno; T Kinoshita; T Takayama; T Kosuge; S Yamazaki; K Maruyama
Journal:  Br J Surg       Date:  1994-08       Impact factor: 6.939

Review 10.  Hepatic resection for noncolorectal nonneuroendocrine metastases.

Authors:  S I Schwartz
Journal:  World J Surg       Date:  1995 Jan-Feb       Impact factor: 3.352

View more
  29 in total

Review 1.  Liver resections in metastatic gastric cancer.

Authors:  Sid P Kerkar; Clinton D Kemp; Itzhak Avital
Journal:  HPB (Oxford)       Date:  2010-11       Impact factor: 3.647

2.  Prognostic significance of radical surgical treatment for gastric cancer patients with synchronous liver metastases.

Authors:  Weijia Wang; Han Liang; Hui Zhang; Xuejun Wang; Qiang Xue; Rupeng Zhang
Journal:  Med Oncol       Date:  2014-09-27       Impact factor: 3.064

3.  Surgery for liver metastasis from gastric cancer.

Authors:  Guido Alberto Massimo Tiberio; Franco Roviello; Annibale Donini; Giovanni de Manzoni
Journal:  Transl Gastroenterol Hepatol       Date:  2016-09-08

4.  Surgical treatment of hepatic metastases from gastric cancer.

Authors:  Silvia Ministrini; Leonardo Solaini; Chiara Cipollari; Silvia Sofia; Elisabetta Marino; Alessia D'Ignazio; Maria Bencivenga; Guido A M Tiberio
Journal:  Updates Surg       Date:  2018-05-29

Review 5.  Role of periostin and its antagonist PNDA-3 in gastric cancer metastasis.

Authors:  Guo-Xiao Liu; Hong-Qing Xi; Xiao-Yan Sun; Bo Wei
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

6.  Systemic chemotherapy as a main strategy for liver metastases from gastric cancer.

Authors:  W Zhang; Y Yu; Y Fang; Y Wang; Y Cui; K Shen; T Liu
Journal:  Clin Transl Oncol       Date:  2015-06-25       Impact factor: 3.405

7.  Survival benefit of surgical treatment for liver metastases from gastric cancer.

Authors:  Toshiki Shinohara; Yoshiaki Maeda; Tomonori Hamada; Noriaki Futakawa
Journal:  J Gastrointest Surg       Date:  2015-02-19       Impact factor: 3.452

8.  Weekly docetaxel and cisplatin plus fluorouracil as a preoperative treatment for gastric cancer patients with synchronous multiple hepatic metastases: a pilot study.

Authors:  Zi-Yu Li; Lei Tang; Lian-Hai Zhang; Zhao-De Bu; Ai-Wen Wu; Xiao-Jiang Wu; Xiang-Long Zong; Qi Wu; Fei Shan; Shuang-Xi Li; Hui Ren; Xiao-Peng Zhang; Jia-Fu Ji
Journal:  Med Oncol       Date:  2009-12-05       Impact factor: 3.064

9.  Surgical resection of hepatic metastases from gastric cancer: outcomes from national series in England.

Authors:  Sheraz R Markar; Hugh Mackenzie; Sameh Mikhail; Muntzer Mughal; Shaun R Preston; Nick D Maynard; Omar Faiz; George B Hanna
Journal:  Gastric Cancer       Date:  2016-03-03       Impact factor: 7.370

Review 10.  Clinical modalities for management of gastric cancer hepatic metastasis.

Authors:  Feng Tao; Jieqing Lv; Wei Wang; Ketao Jin
Journal:  Int J Clin Exp Med       Date:  2015-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.